60 Degrees Pharmaceuticals launching Arakoda

60 Degrees Pharmaceuticals is offering Arakoda (tafenoquine) for the prevention of malaria in adults.

Arakoda was the first anti-malarial product approved by the Food and Drug Administration, for prevention in over 18 years. Arakoda has the potential to protect thousands of U.S. travelers and military personnel from the devastating and life-threatening effects of malaria.

60P's first significant shipment of Arakoda occurred in September, 2019, to the U.S. Army. The product is now commercially available via select retail pharmacy outlets and pharmaceutical wholesalers. 60P continues to work closely with distribution networks and third-party insurance companies to provide extensive access to the product, the company said.

"Malaria is one of the most malicious diseases, on the rise in both U.S. and other parts of the world," said Geoffrey Dow, 60P Pharmaceuticals CEO. "It poses a significant risk to millions of healthy individuals traveling to areas where malaria is endemic, including those traveling for leisure, employees of non-governmental organizations, industrial and business workers, and military forces."

Arakoda is supplied in 100 mg tablets for oral use only. After an initial loading dose prior to traveling, Arakoda is intended to be taken once a week.